Exchange: NASDAQ·Updated 04:10 PM EDT
News
all
press releases
TELA Bio Names Heather Getz CEO
(RTTNews) - On Tuesday, TELA Bio, Inc. (TELA), a commercial-stage medical technology company for soft tissue reconstruction, announced the appointment of Heather Getz as Chief Executive Officer and Director, effective today...
Nasdaq News: Markets
More News
TELA Bio Q1 2026 Earnings Call Transcript
read more...
Benzinga
TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -50.00% and +3.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +36.36% and +68.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -19.32% and +8.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
TELA Bio Analysts Cut Their Forecasts After Q4 Results
TELA Bio (NASDAQ:TELA) reported mixed Q4 results, with higher losses but lower sales than expected. Analysts lowered price targets for the stock.read more...
Benzinga
Amazon To Rally Around 49%? Here Are 10 Top Analyst Forecasts For Wednesday
Top analysts change outlook for top names. Citigroup, Tigress Fin, Piper Sandler, Morgan Stanley, HC Wainwright, Susquehanna, Raymond James and Goldman Sachs adjust price targets for companies like...
Benzinga
TELA Bio (TELA) Q4 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of +11.11% and -0.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +586.28% and +300.65%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.